<SEC-DOCUMENT>0001021771-24-000111.txt : 20240419
<SEC-HEADER>0001021771-24-000111.hdr.sgml : 20240419
<ACCEPTANCE-DATETIME>20240419163805
ACCESSION NUMBER:		0001021771-24-000111
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20240419
DATE AS OF CHANGE:		20240419

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioRestorative Therapies, Inc.
		CENTRAL INDEX KEY:			0001505497
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				301341024
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-278488
		FILM NUMBER:		24858318

	BUSINESS ADDRESS:	
		STREET 1:		40 MARCUS DRIVE
		CITY:			MELVILLE
		STATE:			NY
		ZIP:			11747
		BUSINESS PHONE:		(631) 760-8100

	MAIL ADDRESS:	
		STREET 1:		40 MARCUS DRIVE
		CITY:			MELVILLE
		STATE:			NY
		ZIP:			11747

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stem Cell Assurance, Inc.
		DATE OF NAME CHANGE:	20101110
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>prospectus.htm
<DESCRIPTION>2,513,686 SHARES OF COMMON STOCK
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Certilman Balin
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">Filed Pursuant to Rule 424(b)(3)</div>
    <div><br>
    </div>
    <div>
      <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">Registration No. 333-278488</div>
    </div>
    <div>
      <div style="margin-bottom: 6pt;"><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
    <div style="margin-bottom: 8pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">PROSPECTUS</div>
    <div style="text-align: center; margin-bottom: 8pt;"><img width="208" height="80" src="image0.jpg"></div>
    <div style="text-align: center; margin-bottom: 8pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">2,513,686 Shares of Common Stock</div>
    <div style="text-indent: 36pt; margin-bottom: 8pt; font-family: 'Times New Roman',Times,serif;">This prospectus relates to the offer and sale from time to time of up to 2,513,686 shares of common stock, par value $0.0001 per share, of BioRestorative
      Therapies, Inc. by the selling securityholders listed under the caption &#8220;Selling Securityholders&#8221; on page 7 of this prospectus, or the selling securityholders. All of the shares being offered, when sold, will be sold by the selling securityholders or
      their respective pledgees, donees, assignees, transferees or other successors-in-interest. We are filing the registration statement of which this prospectus is a part to fulfill a contractual obligation to do so, as described in this prospectus. We
      will not receive any of the proceeds from the sale or other disposition of the shares by the selling securityholders.&#160;&#160;</div>
    <div style="text-indent: 36pt; margin-bottom: 8pt; font-family: 'Times New Roman',Times,serif;">The selling securityholders, or their respective pledgees, donees, assignees, transferees or other successors-in-interest, may, from time to time, sell,
      transfer or otherwise dispose of any or all of their shares of our common stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions.&#160;&#160;These dispositions may be at fixed prices, at prevailing
      market prices at the time of sale, at prices relating to the prevailing market price, at varying prices determined at the time of sale or at negotiated prices.&#160;&#160;See &#8220;<a href="#PLANOFDISTRIBUTION">Plan of Distribution</a>&#8221; for additional information.</div>
    <div style="text-indent: 36pt; margin-bottom: 8pt; font-family: 'Times New Roman',Times,serif;">Our common stock is currently traded on the NASDAQ Capital Market under the symbol &#8220;BRTX.&#8221;&#160;&#160;On April 18, 2024, the closing sale price for our common stock
      on the NASDAQ Capital Market was $1.44 per share.</div>
    <div style="text-indent: 36pt; margin-bottom: 8pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Investing in our common stock involves risks.&#160;&#160;You should carefully read the section entitled &#8220;<a href="#RISKFACTORS">Risk Factors</a>&#8221;
      on page 3 of this prospectus before purchasing any shares of common stock offered by this prospectus.</div>
    <div style="text-indent: 36pt; margin-bottom: 8pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
      determined if this prospectus is truthful or complete.&#160;&#160;Any representation to the contrary is a criminal offense.</div>
    <div style="margin-bottom: 8pt;"><br>
    </div>
    <div style="text-align: center; margin-bottom: 8pt; font-family: 'Times New Roman',Times,serif;">This prospectus is dated&#160;April 18, 2024.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; margin-bottom: 8pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">TABLE OF CONTENTS</div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zfd9fbebbd2254092a110c35bc7804e14">

        <tr>
          <td style="width: 91.34%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 8.66%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Page</div>
          </td>
        </tr>
        <tr>
          <td style="width: 91.34%; vertical-align: top;">
            <div><a href="#ABOUTTHISPROSPECTUS"><font style="font-family: 'Times New Roman',Times,serif;">About This Prospectus</font><font style="display: inline-block; text-indent: 0px; width: 423pt;" class="TRGRRTFtoHTMLTab">&#160;</font></a></div>
          </td>
          <td style="width: 8.66%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;"><a href="#ABOUTTHISPROSPECTUS">1</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 91.34%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#WHEREYOUCANOBTAINMOREINFO"><font style="font-family: 'Times New Roman',Times,serif;">Where You Can Obtain More Information</font><font style="display: inline-block; text-indent: 0px; width: 423pt;" class="TRGRRTFtoHTMLTab">&#160;</font></a></div>
          </td>
          <td style="width: 8.66%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;"><a href="#WHEREYOUCANOBTAINMOREINFO">1</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 91.34%; vertical-align: top;">
            <div><a href="#INCORPORATIONOFCERTAININF"><font style="font-family: 'Times New Roman',Times,serif;">Incorporation of Certain Information by Reference</font><font style="display: inline-block; text-indent: 0px; width: 423pt;" class="TRGRRTFtoHTMLTab">&#160;</font></a></div>
          </td>
          <td style="width: 8.66%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;"><a href="#INCORPORATIONOFCERTAININF">2</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 91.34%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#RISKFACTORS"><font style="font-family: 'Times New Roman',Times,serif;">Risk Factors</font><font style="display: inline-block; text-indent: 0px; width: 423pt;" class="TRGRRTFtoHTMLTab">&#160;</font></a></div>
          </td>
          <td style="width: 8.66%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;"><a href="#RISKFACTORS">3</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 91.34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;"><a href="#SPECIALCAUTIONARYNOTEREGA">Special Cautionary Note Regarding Forward-Looking Statements</a></div>
          </td>
          <td style="width: 8.66%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;"><a href="#SPECIALCAUTIONARYNOTEREGA">3</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 91.34%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#PROSPECTUSSUMMARY"><font style="font-family: 'Times New Roman',Times,serif;">Prospectus Summary</font><font style="display: inline-block; text-indent: 0px; width: 423pt;" class="TRGRRTFtoHTMLTab">&#160;</font></a></div>
          </td>
          <td style="width: 8.66%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;"><a href="#PROSPECTUSSUMMARY">4</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 91.34%; vertical-align: top;">
            <div><a href="#USEOFPROCEEDS"><font style="font-family: 'Times New Roman',Times,serif;">Use of Proceeds</font><font style="display: inline-block; text-indent: 0px; width: 423pt;" class="TRGRRTFtoHTMLTab">&#160;</font></a></div>
          </td>
          <td style="width: 8.66%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;"><a href="#USEOFPROCEEDS">6</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 91.34%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#SELLINGSECURITYHOLDERS"><font style="font-family: 'Times New Roman',Times,serif;">Selling Securityholders</font><font style="display: inline-block; text-indent: 0px; width: 423pt;" class="TRGRRTFtoHTMLTab">&#160;</font></a></div>
          </td>
          <td style="width: 8.66%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;"><a href="#SELLINGSECURITYHOLDERS">6</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 91.34%; vertical-align: top;">
            <div><a href="#DESCRIPTIONOFSECURITIES"><font style="font-family: 'Times New Roman',Times,serif;">Description of Securities</font><font style="display: inline-block; text-indent: 0px; width: 423pt;" class="TRGRRTFtoHTMLTab">&#160;</font></a></div>
          </td>
          <td style="width: 8.66%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;"><a href="#DESCRIPTIONOFSECURITIES">9</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 91.34%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#PLANOFDISTRIBUTION"><font style="font-family: 'Times New Roman',Times,serif;">Plan of Distribution</font><font style="display: inline-block; text-indent: 0px; width: 423pt;" class="TRGRRTFtoHTMLTab">&#160;</font></a></div>
          </td>
          <td style="width: 8.66%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;"><a href="#PLANOFDISTRIBUTION">16</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 91.34%; vertical-align: top;">
            <div><a href="#LEGALMATTERS"><font style="font-family: 'Times New Roman',Times,serif;">Legal Matters</font><font style="display: inline-block; text-indent: 0px; width: 423pt;" class="TRGRRTFtoHTMLTab">&#160;</font></a></div>
          </td>
          <td style="width: 8.66%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;"><a href="#LEGALMATTERS">18</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 91.34%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#EXPERTS"><font style="font-family: 'Times New Roman',Times,serif;">Experts</font><font style="display: inline-block; text-indent: 0px; width: 423pt;" class="TRGRRTFtoHTMLTab">&#160;</font></a></div>
          </td>
          <td style="width: 8.66%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;"><a href="#EXPERTS">18</a></div>
          </td>
        </tr>

    </table>
    <div style="text-align: center;"><br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">This prospectus includes references to our federally registered trademarks, <font style="font-style: italic;">BioRestorative Therapies and Dragonfly design</font>, <font style="font-style: italic;">BRTX-100, ThermoStem and BRTX</font>.&#160; The Dragonfly Logo is also registered with the U.S. Copyright Office. This prospectus also includes references to trademarks, trade names and service marks that are the property of
      other organizations. Solely for convenience, trademarks and trade names referred to in this prospectus appear without the &#174;, <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">SM </sup>or &#8482; symbols, and copyrighted content appears without the use of the symbol &#169;, but the absence of use of
      these symbols does not reflect upon the validity or enforceability of the intellectual property owned by us or third parties.</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%1%%%-->
    <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><a name="ABOUTTHISPROSPECTUS"><!--Anchor--></a>ABOUT THIS PROSPECTUS</div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">This prospectus is part of a registration statement that we have filed with the Securities and Exchange Commission, or the SEC, pursuant to which the selling securityholders
      named herein may, from time to time, offer and sell or otherwise dispose of the shares of Common Stock covered by this prospectus. You should rely only on the information contained or incorporated by reference into this prospectus and any related
      prospectus supplement. We have not, and the selling securityholders have not, authorized anyone to provide you with different information. No&#160;one is making offers to sell or seeking offers to buy these securities in any jurisdiction where the offer
      or sale is not permitted. You should assume that the information contained in this prospectus and any prospectus supplement is accurate only as of the date on the front of this prospectus or the prospectus supplement, as applicable, and that any
      information incorporated by reference into this prospectus or any prospectus supplement is accurate only as of the date given in the document incorporated by reference, regardless of the time of delivery of this prospectus, any applicable prospectus
      supplement or any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date.</div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete
      information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration
      statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the section entitled &#8220;<a href="#WHEREYOUCANOBTAINMOREINFO">Where You Can Obtain More Information</a>.&#8221;</div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">This prospectus and the information incorporated herein by reference includes trademarks, service marks and trade names owned by us or others. All trademarks, service marks and
      trade names included or incorporated by reference into this prospectus or any applicable prospectus supplement are the property of their respective owners.</div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">This summary is not complete and does not contain all of the information you should consider before investing in the securities offered by this prospectus. Before making an
      investment decision, you should read the entire prospectus, and any prospectus supplement, carefully, including the sections titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our
      financial statements and the notes to the financial statements incorporated by reference into this prospectus.</div>
    <div><br>
    </div>
    <div><font style="display: inline-block; text-indent: 0px; width: 36pt;" class="TRGRRTFtoHTMLTab">&#160;</font><font style="font-family: 'Times New Roman',Times,serif;">Unless the context of this prospectus indicates otherwise, the terms &#8220;BioRestorative,&#8221;
        the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refer to BioRestorative Therapies, Inc. and its consolidated subsidiaries.</font></div>
    <div><br>
    </div>
    <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><a name="WHEREYOUCANOBTAINMOREINFO"><!--Anchor--></a>WHERE YOU CAN OBTAIN MORE INFORMATION</div>
    <div style="text-indent: 36pt; margin-bottom: 8pt; font-family: 'Times New Roman',Times,serif;">We are subject to the information requirements of the Securities Exchange Act of 1934, as amended, referred to as the Exchange Act, which means that we are
      required to file annual, quarterly and current reports, proxy statements and other information with the SEC, all of which are available at the Public Reference Room of the SEC at 100 F Street, NE, Washington D.C. 20549. You may also obtain copies of
      these reports, proxy statements and other information from the Public Reference Room of the SEC, at prescribed rates, by calling 1-800-SEC-0330. The SEC maintains an Internet website at http://www.sec.gov where you can access reports, proxy
      statements, information and registration statements, and other information regarding us that we file electronically with the SEC. In addition, we make available, without charge, through our website, www.biorestorative.com, electronic copies of
      various filings with the SEC, including copies of Annual Reports on Form 10-K. Information on our website should not be considered a part of this prospectus, and we do not intend to incorporate into this prospectus any information contained on our
      website.</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">1</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; margin-top: 4.25pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><a name="INCORPORATIONOFCERTAININF"><!--Anchor--></a>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#160;</div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">The SEC allows us to incorporate by reference information from other documents that we file with it, which means that we can disclose important information to you by referring
      you to those documents. The information incorporated by reference is considered to be part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we filed with the SEC prior to the date of this
      prospectus. We incorporate by reference into this prospectus and the registration statement of which this prospectus is a part the information or documents listed below that we have filed with the SEC (Commission File No. 001-37603):</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zef54fa517c4246448233a8eec370ae5d">

        <tr>
          <td style="width: 7.34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 3.67%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#9679;</div>
          </td>
          <td style="width: 88.99%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1505497/000149315224012056/form10-k.htm">Our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC
                on April 1, 2024</a>;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.34%; vertical-align: top;">&#160;</td>
          <td style="width: 3.67%; vertical-align: top;">&#160;</td>
          <td style="width: 88.99%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 7.34%; vertical-align: top;">&#160;</td>
          <td style="width: 3.67%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#9679;</div>
          </td>
          <td style="width: 88.99%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1505497/000102177124000033/brt8k.htm">Our Current Report on Form 8-K for an event dated February 6, 2024, filed with the SEC on
                February 8, 2024</a>; and</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.34%; vertical-align: top;">&#160;</td>
          <td style="width: 3.67%; vertical-align: top;">&#160;</td>
          <td style="width: 88.99%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 7.34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 3.67%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#9679;</div>
          </td>
          <td style="width: 88.99%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;"><a href="https://www.sec.gov/Archives/edgar/data/1505497/000102177121000082/form8a12b.htm">the description of our common stock contained in our registration statement on Form 8-A filed
                with the SEC on November 4, 2021 (File No. 001-37603)</a>, and any amendment or report filed with the SEC for the purpose of updating the description.</div>
          </td>
        </tr>

    </table>
    <div style="text-indent: -18pt; margin-left: 72pt; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">We also incorporate by reference into this prospectus all documents (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such
      form that are related to such items) that are subsequently filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of the offering of the securities made by this prospectus. These documents
      include periodic reports, such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as proxy statements.</div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">Any statement contained in this prospectus or in a document incorporated or deemed to be incorporated by reference into this prospectus will be deemed to be modified or
      superseded to the extent that a statement contained in this prospectus or any subsequently filed document that is deemed to be incorporated by reference into this prospectus modifies or supersedes the statement.</div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">We will furnish without charge to you, on written or oral request, a copy of any or all of the documents incorporated by reference, including exhibits to these documents. You
      should direct any requests for documents to:</div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">BioRestorative Therapies, Inc.</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">40 Marcus Drive, Suite One</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">Melville, New York 11747</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">(631) 760-8100</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">Attention: Secretary</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">fsilva@biorestorative.com</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">2</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><a name="RISKFACTORS"><!--Anchor--></a>RISK FACTORS</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#160;</div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">An investment in our common stock involves a high degree of risk. Prior to making a decision about investing in our common stock, you should consider carefully the specific
      risk factors discussed in Item 1A (Risk Factors) of our most recent <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1505497/000149315224012056/form10-k.htm">Annual Report on Form 10-K for the year ended December 31, 2023</a>, as filed with
      the SEC, and which is incorporated in this prospectus by reference in its entirety, as well as any amendment or updates to our risk factors reflected in subsequent filings with the SEC, including any prospectus supplement hereto. These risks and
      uncertainties are not the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us, or that we currently view as immaterial, may also impair our business. If any of the risks or uncertainties described in our
      SEC filings or any additional risks and uncertainties actually occur, our business, financial condition, results of operations and cash flow could be materially and adversely affected. In that case, the trading price of our common stock could decline
      and you might lose all or part of your investment.</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><!--Anchor--><a name="SPECIALCAUTIONARYNOTEREGA"><!--Anchor--></a>SPECIAL CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#160;</div>
    <div>
      <div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">Some of the statements in or incorporated by reference into this prospectus contain &#8220;forward-looking statements.&#8221; Forward-looking statements are made based on our
        management&#8217;s expectations and beliefs concerning future events impacting our company and are subject to uncertainties and factors relating to our operations and economic environment, all of which are difficult to predict and many of which are
        beyond our control. You can identify these statements from our use of the words &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;believe,&#8221; &#8220;intend,&#8221; &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;target,&#8221; &#8220;plan,&#8221; &#8220;may&#8221; and similar expressions. These forward-looking statements may include, among
        other things:</div>
    </div>
    <div>
      <div style="text-align: justify; text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zdc02b5f8074544c099c843b61965f1dc">

        <tr>
          <td style="width: 2.51%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 2.5%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">statements relating to projected growth and management&#8217;s long-term performance goals;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.51%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 2.5%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">statements relating to the anticipated effects on results of operations or our financial condition</div>
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">from expected developments or events;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.51%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 2.5%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">statements relating to our business and growth strategies; and</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.51%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 2.5%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">any other statements which are not historical facts.</div>
          </td>
        </tr>

    </table>
    <div>
      <div style="text-align: justify; text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    </div>
    <div>
      <div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause our actual results, performance or achievements, or
        industry results, to differ materially from our expectations of future results, performance or achievements expressed or implied by these forward-looking statements. These forward-looking statements may not be realized due to a variety of factors,
        including without limitation:</div>
    </div>
    <div>
      <div style="text-align: justify; text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zc7a1a756f4924c18be0976f8be12b257">

        <tr>
          <td style="width: 2.51%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 2.5%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">our current and anticipated cash needs and our need for additional financing;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.51%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 2.5%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">federal, state and foreign regulatory requirements;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.51%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 2.5%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">our ability to conduct clinical trials with respect to our products and services;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.51%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 2.5%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">our ability to develop and commercialize our products and services;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.51%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 2.5%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">our ability to enter into agreements to implement our business strategy;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.51%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 2.5%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">the acceptance of our products and services by patients and the medical community;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.51%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 2.5%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">our ability to secure necessary media and reagents, as well as devices, materials and systems,</div>
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">for our clinical trials and commercial production;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.51%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 2.5%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">our manufacturing capabilities to produce our products;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.51%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 2.5%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">our ability to obtain brown adipose (fat) tissue in connection with our&#160;<font style="font-style: italic;">ThermoStem Program</font>;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.51%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 2.5%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">our ability to maintain exclusive rights with respect to our licensed disc/spine technology;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">3</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 2.51%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 2.5%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">our ability to protect our intellectual property;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.51%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 2.5%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">our ability to obtain and maintain an adequate level of product liability insurance;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.51%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 2.5%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">our ability to obtain third party reimbursement for our products and services from private and</div>
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">governmental insurers;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.51%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 2.5%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">the effects of competition in our market areas;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.51%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 2.5%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">our reliance on certain key personnel;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.51%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 2.5%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">further sales or other dilution of our equity, which may adversely affect the market price of our</div>
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">common stock; and</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.51%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 2.5%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">&#9679;</div>
          </td>
          <td style="width: 95%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">other factors and risks referred to under &#8220;<a href="#RISKFACTORS">Risk Factors</a>&#8221; on page 3 of this prospectus.</div>
          </td>
        </tr>

    </table>
    <div>
      <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    </div>
    <div>
      <div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">You should not place undue reliance on any forward-looking statement. We undertake no obligation to update any forward-looking statement to reflect events or circumstances
        after the date of this prospectus or to reflect the occurrence of unanticipated events.</div>
    </div>
    <div>
      <div style="text-align: justify; text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    </div>
    <div>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><a name="PROSPECTUSSUMMARY"><!--Anchor--></a>PROSPECTUS SUMMARY</div>
      <div><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Who We Are</div>
    </div>
    <div style="text-align: justify; margin-right: 8.7pt; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">We are a life sciences company focused on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult
      (non-embryonic) stem cells. Our two core developmental programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:</div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z886b3d3639784da4a2ffcf73cd3a3b37">

          <tr>
            <td style="width: 58.5pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 40.5pt; font-family: 'Times New Roman',Times,serif;">&#8226;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold; font-style: italic;">Disc/Spine Program (brtxDisc).&#160;</font><font style="font-size: 10pt;">Our lead cell therapy
                  candidate, <font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">BRTX-100</font>, is a product formulated from autologous (or a person&#8217;s own) cultured mesenchymal stem cells, or MSCs, collected from the patient&#8217;s
                  bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure. The <font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">BRTX-100</font> production process utilizes proprietary technology and involves collecting bone marrow and whole blood from a patient, isolating and culturing stem cells from the bone marrow and
                  cryopreserving the cells. In an outpatient procedure, <font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">BRTX-100</font> is to be injected by a physician into the patient&#8217;s damaged disc. The treatment is
                  intended for patients whose pain has not been alleviated by non-surgical procedures or conservative therapies and who potentially face the prospect of surgical procedures. We have commenced a Phase 2 clinical trial investigating the use
                  of <font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">BRTX-100</font> in the treatment of chronic lower back pain arising from degenerative disc disease.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z20166120520e422dac05ecb267ad5a9d">

          <tr>
            <td style="width: 58.5pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 40.5pt; font-family: 'Times New Roman',Times,serif;">&#8226;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold; font-style: italic;">Metabolic Program (ThermoStem)</font><font style="font-size: 10pt;">. We are developing a
                  cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) to generate brown adipose tissue, or BAT. We refer to this as our <font style="font-family: 'Times New Roman',Times,serif; font-style: italic;">ThermoStem Program</font>. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research conducted by us and others indicates that increased
                  amounts of brown fat in animals may be responsible for additional caloric burning, as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and
                  diabetes.&#160;</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="margin-left: 36pt; font-family: 'Times New Roman',Times,serif;">&#160;&#160;</div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">We have also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs (and other parts of
      the body). We anticipate that FDA approval or clearance will be necessary for this device prior to commercialization. We do not intend to utilize this device in connection with our Phase 2 clinical trial with regard to <font style="font-style: italic;">BRTX-100</font>.</div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">4</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">The patents and patent applications for the&#160;<font style="font-style: italic;">Disc/Spine Program</font>, the&#160;<font style="font-style: italic;">ThermoStem Program</font>&#160;and the
      curved needle device are listed under &#8220;Business - Technology; Research and Development&#8221; in Part I of our <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1505497/000149315224012056/form10-k.htm">Annual Report on Form 10-K for the year ended
        December 31, 2023</a> incorporated herein by reference.</div>
    <div><br>
    </div>
    <div style="text-align: center; margin-right: 8.7pt; margin-left: 8.7pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Corporate Information</div>
    <div style="margin-right: 8.7pt; margin-left: 8.7pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#160;</div>
    <div style="text-indent: 36pt; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">We are a Nevada corporation. Our headquarters are located at 40 Marcus Drive, Suite One, Melville, New York 11747. Our telephone
        number is (631) 760-8100. We maintain certain information on our website at www.biorestorative.com. The information on our website is not (and should not be considered) part of this prospectus and is not incorporated into this prospectus by
        reference.</font></div>
    <div><br>
    </div>
    <div style="text-align: center; margin-bottom: 8pt; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">The
        Offering</font></div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">We have entered into agreements with the selling securityholders pursuant to which we have agreed to register for resale the shares of common stock issuable to the selling
      securityholders upon the exercise of certain warrants held by them for the purchase of an aggregate of 2,513,686 shares of common stock, or the Warrants. We have agreed to maintain the effectiveness of the registration statement until the selling
      securityholders no longer own any of the Warrants or the underlying shares of common stock. <font style="font-weight: bold;">&#160;</font></div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">The following is a brief summary of this offering.&#160;&#160;You should read the entire prospectus carefully, including &#8220;<a href="#RISKFACTORS">Risk Factors</a>&#8221; on page 3, the
      information referred to therein and the information, including financial information, incorporated by reference into this prospectus.</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zad166ad3c0fe47b1856e5120a420a516">

        <tr>
          <td style="width: 43.58%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">Common Stock Outstanding</div>
          </td>
          <td style="width: 2.46%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 53.96%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">6,769,919 shares</div>
          </td>
        </tr>
        <tr>
          <td style="width: 43.58%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 2.46%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 53.96%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 43.58%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">Common Stock Offered by the</div>
            <div style="font-family: 'Times New Roman',Times,serif;">Selling Securityholders</div>
          </td>
          <td style="width: 2.46%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 53.96%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
            <div style="font-family: 'Times New Roman',Times,serif;">2,513,686 shares</div>
          </td>
        </tr>
        <tr>
          <td style="width: 43.58%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 2.46%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 53.96%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 43.58%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">Terms of the Offering</div>
          </td>
          <td style="width: 2.46%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 53.96%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">The selling securityholders will determine when and how they will sell the shares of common stock offered by this prospectus, as described in "<a href="#PLANOFDISTRIBUTION">Plan of Distribution</a>."</div>
          </td>
        </tr>
        <tr>
          <td style="width: 43.58%; vertical-align: top;">&#160;</td>
          <td style="width: 2.46%; vertical-align: top;">&#160;</td>
          <td style="width: 53.96%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 43.58%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">Use of Proceeds</div>
          </td>
          <td style="width: 2.46%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 53.96%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">We will receive no proceeds from the sale of the shares of common stock being offered by the selling securityholders by this prospectus.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 43.58%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 2.46%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 53.96%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 43.58%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">Risk Factors</div>
          </td>
          <td style="width: 2.46%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
            <div>&#160;</div>
          </td>
          <td style="width: 53.96%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">An investment in the shares offered by this prospectus involves a degree of risk and should be considered only by persons who can afford the loss of their entire
              investment. See &#8220;<a href="#RISKFACTORS">Risk Factors</a>&#8221; on page 3.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 43.58%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 2.46%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 53.96%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 43.58%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">Nasdaq Capital Market Symbol</div>
          </td>
          <td style="width: 2.46%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 53.96%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#8220;BRTX&#8221;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">5</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><a name="USEOFPROCEEDS"><!--Anchor--></a>USE OF PROCEEDS</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#160;</div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">We are not selling any securities in this offering and we will not receive any of the proceeds from the sale of shares of our common stock by the selling securityholders. The
      selling securityholders will receive all of the proceeds from any sales of the shares of our common stock offered hereby. However, we will incur expenses in connection with the registration of the shares of our common stock offered hereby, including
      legal and accounting fees.</div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">We will receive the exercise price upon any exercise of the Warrants. If the outstanding Warrants are exercised in full, we would receive gross proceeds of $6,108,255. We
      currently intend to use such proceeds, if any, for general corporate purposes and working capital, including in connection with our clinical trial and other business initiatives. The holders of the Warrants are not obligated to exercise the Warrants,
      and we cannot predict whether or when, if ever, the holders of the Warrants will choose to exercise the Warrants, in whole or in part.</div>
    <div><br>
    </div>
    <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><a name="SELLINGSECURITYHOLDERS"><!--Anchor--></a>SELLING SECURITYHOLDERS</div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">The following table identifies the selling securityholders and indicates certain information known to us based upon written statements provided by the selling securityholders
      or through our transfer agent records with respect to: (i) the number of shares of common stock beneficially owned by the selling securityholders prior to the offering of the shares of common stock covered by this prospectus; (ii) the maximum number
      of shares of common stock the selling securityholders may sell under this prospectus; (iii) the number of shares of common stock that the selling securityholders would own following the sale of all of the shares of common stock they may sell under
      this prospectus; and (iv) the percentage of the outstanding common stock that the selling securityholders would own following the sale of all of the shares of common stock they may sell under this prospectus.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">The selling securityholders, or their respective pledgees, donees, assignees, transferees or other successors-in-interest, may sell some, all or none of their shares of common
      stock covered by this prospectus from time to time. We do not know how long the selling securityholders will hold their shares of common stock covered by this prospectus before selling them.&#160; We currently have no agreements, arrangements or
      understandings with the selling securityholders regarding the sale of any of the shares of common stock. We do not know when or in what amounts the selling securityholders may sell or otherwise dispose of the shares of common stock covered
      hereby.&#160;&#160;As a result, we cannot estimate the number of shares that will be held by the selling securityholders after completion of the sale of shares of common stock covered by this prospectus.&#160;&#160;However, for purposes of this table, we have assumed
      that all of the Warrants will be exercised in full and that all of the shares of common stock covered by this prospectus will be sold by the selling securityholders.&#160; The percentages of common stock beneficially owned are based on 6,769,919 shares of
      common stock outstanding on March 20, 2024 (exclusive of the 1,351,580 shares of common stock issuable to Auctus Fund, LLC, or Auctus, as discussed in footnote (4) to the following table).</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">6</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" class="cfttable" id="z2535d696ef3746fba21a0395fbafc432" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">

        <tr>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center;"><font style="font-family: 'Times New Roman',Times,serif;">&#160;</font><font style="font-weight: bold;">Name of Selling</font></div>
            <div style="text-align: center; font-weight: bold;">Securityholder</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Number of</div>
            <div style="text-align: center; font-weight: bold;">Shares of</div>
            <div style="text-align: center; font-weight: bold;"> Common Stock</div>
            <div style="text-align: center; font-weight: bold;">Beneficially</div>
            <div style="text-align: center; font-weight: bold;">Owned Prior to Offering(1)</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Number of</div>
            <div style="text-align: center; font-weight: bold;">Shares of</div>
            <div style="text-align: center; font-weight: bold;">Common Stock</div>
            <div style="text-align: center; font-weight: bold;">Offered Hereby</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Number of Shares of Common Stock</div>
            <div style="text-align: center; font-weight: bold;">Beneficially Owned After Offering</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Percentage</div>
            <div style="text-align: center; font-weight: bold;"> of</div>
            <div style="text-align: center; font-weight: bold;">Class After</div>
            <div style="text-align: center; font-weight: bold;">Offering(14)</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">Altium Growth Fund, LP</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">150,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">(2)</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">150,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">-0-</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">-</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 52%;">
            <div style="font-family: 'Times New Roman',Times,serif;">Armistice Capital, LLC</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-family: 'Times New Roman',Times,serif;">300,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">
            <div style="font-family: 'Times New Roman',Times,serif;">(3)</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-family: 'Times New Roman',Times,serif;">300,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-family: 'Times New Roman',Times,serif;">-0-</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-family: 'Times New Roman',Times,serif;">-</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 52%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">Auctus Fund, LLC</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">679,753</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">(4)</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">1,257,435</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">(4)<br>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;"><br>
            </div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">(4)</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;"><br>
            </div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 52%;">
            <div style="font-family: 'Times New Roman',Times,serif;">Bigger Capital Fund, LP</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-family: 'Times New Roman',Times,serif;">65,625</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">
            <div style="font-family: 'Times New Roman',Times,serif;">(5)</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-family: 'Times New Roman',Times,serif;">65,625</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-family: 'Times New Roman',Times,serif;">-0-</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-family: 'Times New Roman',Times,serif;">-</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 52%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">CVI Investments, Inc.</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">112,500</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">(6)</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">112,500</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">-0-</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">-</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 52%;">
            <div style="font-family: 'Times New Roman',Times,serif;">District 2 Capital Fund LP</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-family: 'Times New Roman',Times,serif;">65,625</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">
            <div style="font-family: 'Times New Roman',Times,serif;">(7)</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-family: 'Times New Roman',Times,serif;">65,625</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-family: 'Times New Roman',Times,serif;">-0-</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-family: 'Times New Roman',Times,serif;">-</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 52%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">Empery Asset Master, Ltd.</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">60,062</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">(8)</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">60,062</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">-0-</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">-</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 52%;">
            <div style="font-family: 'Times New Roman',Times,serif;">Empery Tax Efficient, LP</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-family: 'Times New Roman',Times,serif;">30,008</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">
            <div style="font-family: 'Times New Roman',Times,serif;">(9)</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-family: 'Times New Roman',Times,serif;">30,008</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-family: 'Times New Roman',Times,serif;">-0-</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-family: 'Times New Roman',Times,serif;">-</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 52%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">Empery Tax Efficient III, LP</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">22,431</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">(10)</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">22,431</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">-0-</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">-</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 52%;">
            <div style="font-family: 'Times New Roman',Times,serif;">Hudson Bay Master Fund Ltd.</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-family: 'Times New Roman',Times,serif;">150,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">
            <div style="font-family: 'Times New Roman',Times,serif;">(11)</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-family: 'Times New Roman',Times,serif;">150,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-family: 'Times New Roman',Times,serif;">-0-</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-family: 'Times New Roman',Times,serif;">-</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 52%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">L1 Capital Global Opportunities Master Fund</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">131,250</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">(12)</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">131,250</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">-0-</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">
            <div style="font-family: 'Times New Roman',Times,serif;">-</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 52%;">
            <div style="font-family: 'Times New Roman',Times,serif;">Sabby Volatility Warrant Master Fund, Ltd.</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-family: 'Times New Roman',Times,serif;">345,200</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">
            <div style="font-family: 'Times New Roman',Times,serif;">(13)</div>
          </td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-family: 'Times New Roman',Times,serif;">168,750</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-family: 'Times New Roman',Times,serif;">176,450</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftguttercell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftcurrcell" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" class="cftnumcell" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
            <div style="font-family: 'Times New Roman',Times,serif;">1.9</div>
          </td>
          <td valign="bottom" nowrap="nowrap" class="cftfncell" colspan="1" style="vertical-align: bottom; width: 1%;">
            <div style="font-family: 'Times New Roman',Times,serif;">%</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">_________</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zb1ea1368aaf94578b944c4d0c57a97e6">

        <tr>
          <td style="width: 8.22%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(1)</div>
          </td>
          <td style="width: 91.78%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">The warrants included in the number of shares of common stock beneficially owned are subject to a beneficial ownership limitation of 4.99% (or, in the case of Auctus, 9.99%), which such
              limitation restricts the selling securityholder from exercising that portion of the warrants that would result in the selling securityholder and its affiliates owning, after the exercise, a number of shares of common stock in excess of the
              beneficial ownership limitation.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.22%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(2)</div>
          </td>
          <td style="width: 91.78%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">Represents shares of common stock issuable upon exercise of the Warrants. Altium Capital Management, LP, the investment manager of Altium Growth Fund, LP, has voting and investment power
              over these securities. Jacob Gottlieb is the managing member of Altium Capital Growth GP, LLC, which is the general partner of Altium Growth Fund, LP. Each of Altium Growth Fund, LP and Jacob Gottlieb disclaims beneficial ownership over these
              securities. The principal address of Altium Capital Management, LP is 152 West 57th Street, 20th Floor, New York, NY 10019</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.22%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(3)</div>
          </td>
          <td style="width: 91.78%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">Represents shares of common stock issuable upon exercise of the Warrants. The securities are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company, or the
              Master Fund, and may be deemed to be beneficially owned by: (i) Armistice Capital, LLC , or Armistice Capital, as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital. The address of
              Armistice Capital Master Fund Ltd. is c/o Armistice Capital, LLC, 510 Madison Avenue, 7<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Floor, New York, NY 10022.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.22%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(4)</div>
          </td>
          <td style="width: 91.78%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">Auctus holds the Warrants for the purchase of up to 1,257,435 shares of our common stock. In addition, Auctus owns 1,398,158 shares of our Series B preferred stock which are convertible
              into an aggregate of 1,398,158 shares of our common stock. In connection with the transaction in which the Warrants were issued to Auctus, we issued to Auctus certain shares of common stock and have agreed to issue to Auctus, upon receipt of
              notice from Auctus, subject to the limitation discussed below, 1,351,580 shares of common stock, or the Additional Shares. However, the Warrants are not exercisable for the purchase of our common stock, such Series B preferred stock is not
              convertible into shares of our common stock, and the Additional Shares are not issuable to the extent Auctus would beneficially own, after such exercise and/or conversion and/or issuance, more than 9.99% of our outstanding shares of common
              stock. Auctus has advised that, as of March 20, 2024, it owned 645,320 shares of common stock, which represented 9.5% of the then 6,769,919 outstanding shares of common stock and that the Additional Shares are issuable to it, upon notice from
              it, to the extent that such issuances would not result in Auctus beneficially owning after such issuances more than 9.99% of our outstanding shares of common stock.&#160; Based upon the foregoing, as of March 20, 2024, 34,433 Additional Shares are
              issuable to Auctus (to comply with the 9.99% beneficial ownership limitation), the remaining Additional Shares are not issuable, the Warrants are not currently exercisable for the purchase of shares of common stock and the Series B preferred
              stock is not convertible into shares of common stock.&#160; The number of shares of common stock reflected in the table above as being beneficially owned by Auctus prior to the offering equals 9.99% of our outstanding common stock as of March 20,
              2024 (after giving effect to issuance to Auctus of the 34,433 Additional Shares).</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">7</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 8.22%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(5)</div>
          </td>
          <td style="width: 91.78%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">Represents shares of common stock issuable upon exercise of the Warrants.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.22%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(6)</div>
          </td>
          <td style="width: 91.78%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">Represents shares of common stock issuable upon exercise of the Warrants. Heights Capital Management, Inc., the authorized agent of CVI Investments, Inc., or CVI, has discretionary
              authority to vote and dispose of the shares held by CVI and may be deemed to be the beneficial owner of these shares. Martin Kobinger, in his capacity as Investment Manager of Heights Capital Management, Inc., may also be deemed to have
              investment discretion and voting power over the shares held by CVI.&#160; Mr. Kobinger disclaims any such beneficial ownership of the shares.&#160; CVI Investments, Inc. is affiliated with one or more FINRA members, none of whom are currently expected
              to participate in the sale pursuant to the prospectus contained in the registration statement of shares issuable to the investor upon the exercise of the Warrants.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.22%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(7)</div>
          </td>
          <td style="width: 91.78%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">Represents shares of common stock issuable upon exercise of the Warrants.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.22%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(8)</div>
          </td>
          <td style="width: 91.78%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">Represents shares of common stock issuable upon exercise of the Warrants.&#160; Empery Asset Management LP, the authorized agent of Empery Asset Master Ltd, or EAM, has discretionary authority
              to vote and dispose of the shares held by EAM and may be deemed to be the beneficial owner of these shares. Martin Hoe and Ryan Lane, in their capacity as investment managers of Empery Asset Management LP, may also be deemed to have
              investment discretion and voting power over the shares held by EAM. EAM, Mr. Hoe and Mr. Lane each disclaim any beneficial ownership of these shares.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.22%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(9)</div>
          </td>
          <td style="width: 91.78%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">Represents shares of common stock issuable upon exercise of the Warrants. Empery Asset Management LP, the authorized agent of Empery Tax Efficient, LP, or ETE, has discretionary authority
              to vote and dispose of the shares held by ETE and may be deemed to be the beneficial owner of these shares. Martin Hoe and Ryan Lane, in their capacity as investment managers of Empery Asset Management LP, may also be deemed to have
              investment discretion and voting power over the shares held by ETE. ETE, Mr. Hoe and Mr. Lane each disclaim any beneficial ownership of these shares.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.22%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(10)</div>
          </td>
          <td style="width: 91.78%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">Represents shares of common stock issuable upon exercise of the Warrants.&#160; Empery Asset Management LP, the authorized agent of Empery Tax Efficient III, LP, or ETE III, has discretionary
              authority to vote and dispose of the shares held by ETE III and may be deemed to be the beneficial owner of these shares. Martin Hoe and Ryan Lane, in their capacity as investment managers of Empery Asset Management LP, may also be deemed to
              have investment discretion and voting power over the shares held by ETE III. ETE III, Mr. Hoe and Mr. Lane each disclaim any beneficial ownership of these shares.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.22%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(11)</div>
          </td>
          <td style="width: 91.78%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">Represents shares of common stock issuable upon exercise of the Warrants.&#160; Hudson Bay Capital Management LP, the investment manager of Hudson Bay Master Fund Ltd., has voting and
              investment power over these securities. Sander Gerber is the managing member of Hudson Bay Capital GP LLC, which is the general partner of Hudson Bay Capital Management LP. Each of Hudson Bay Master Fund Ltd. and Sander Gerber disclaims
              beneficial ownership over these securities.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">8</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 8.22%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(12)</div>
          </td>
          <td style="width: 91.78%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">Represents shares of common stock issuable upon exercise of the Warrants.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.22%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(13)</div>
          </td>
          <td style="width: 91.78%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">Includes 168,750 shares of common stock issuable upon exercise of the Warrants. Sabby Management, LLC is the investment manager of Sabby Volatility Warrant Master Fund, Ltd. and shares
              voting and investment power with respect to these shares in this capacity. As manager of Sabby Management, LLC, Hal Mintz also shares voting and investment power on behalf of Sabby Volatility Warrant Master Fund, Ltd. Each of Sabby
              Management, LLC and Hal Mintz disclaims beneficial ownership of the securities listed except to the extent of their pecuniary interest therein.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.22%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">(14)</div>
          </td>
          <td style="width: 91.78%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">Percentage assumes the exercise of all of the Warrants for the purchase of an aggregate of 2,513,686 shares of common stock and that, following such exercises, the number of shares of
              common stock outstanding will be 9,283,605 plus the 34,433 Additional Shares currently issuable to Auctus.</div>
          </td>
        </tr>

    </table>
    <div style="margin-top: 12pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Relationship with Selling Securityholders</div>
    <div style="text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">&#160;In November 2021, we issued to the selling securityholders (other than Auctus) certain warrants, among other securities, pursuant to an underwritten
      public offering. In addition, we concurrently issued to Auctus certain warrants, among other securities, pursuant to an exchange agreement between Auctus and us.</div>
    <div style="text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">On February 6, 2024, we entered into agreements with the selling securityholders to exercise the warrants issued to them in November 2021, which were
      exercisable for the purchase of an aggregate of 3,351,580 shares of common stock, or the Existing Warrants, at a reduced exercise price of $2.33 per share. Certain of the shares of common stock issuable to Auctus pursuant to the exercise of the
      Existing Warrants are being held in abeyance due to the maximum beneficial ownership limitation described in footnote (3) to the Selling Securityholders table.</div>
    <div style="text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">In consideration for the immediate exercise of the Existing Warrants for cash and the payment of $0.125 per share underlying the Warrants, the selling
      securityholders received the Warrants to purchase shares of common stock in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, or the Securities Act.&#160; The Warrants will be exercisable for a period of five years
      into an aggregate of up to 2,513,686 shares of common stock at an exercise price of $2.43 per share.</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><a name="DESCRIPTIONOFSECURITIES"><!--Anchor--></a>DESCRIPTION OF SECURITIES</div>
    <div><br>
    </div>
    <div style="text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif;">This prospectus contains a summary description of the common stock that may be offered from time to time by the selling securityholders.&#160; This summary description does not
      purport to be complete and is subject to, and qualified in its entirety by reference to, the more complete descriptions thereof set forth in our amended and restated articles of incorporation, which we refer to as our charter, and our bylaws, each as
      amended to date. The applicable prospectus supplement may add, update or change the terms and conditions of the securities as described in this prospectus.</div>
    <div style="text-align: justify; text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">9</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Authorization</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif;">Our authorized capital stock consists of 95,000,000 shares of capital stock. We are authorized to issue 75,000,000 shares of common stock, par value $0.0001 per share, and
      20,000,000 shares of preferred stock, par value $0.01 per share.</div>
    <div style="text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif;">As of March 20, 2024, there were 6,769,919 shares of common stock issued and outstanding (exclusive of the 1,351,580 Additional Shares issuable to Auctus as discussed under
      Selling Securityholders above) and 1,398,158 shares of Series B preferred stock issued and outstanding.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Common Stock</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-indent: 22.5pt; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-style: italic;">Dividend Rights. </font><font style="font-size: 10pt;">Subject to preferences that may be applicable to
        any shares of our preferred stock that may be outstanding, the holders of our common stock are entitled to share ratably in such dividends as may be declared by our Board of Directors out of funds legally available therefor.</font></div>
    <div style="text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-indent: 22.5pt; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-style: italic;">Voting Rights. </font><font style="font-size: 10pt;">Each share of our common stock entitles its holder
        to one vote in the election of directors as well as all other matters to be voted on by stockholders.</font></div>
    <div style="text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-indent: 22.5pt; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-style: italic;">No Preemptive Rights. </font><font style="font-size: 10pt;">Holders of our common stock do not have any
        preemptive rights to subscribe for additional shares on a pro rata basis or otherwise when additional shares are offered for sale by us.</font></div>
    <div style="text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-indent: 22.5pt; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-style: italic;">Liquidation Rights. </font><font style="font-size: 10pt;">Subject to preferences that may be applicable
        to any shares of our preferred stock that may be outstanding, in the event of our liquidation, dissolution or winding up, the holders of our common stock would be entitled to receive, pro rata, after payment of all of our debts and liabilities, all
        of our remaining assets available for distribution.</font></div>
    <div style="text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-indent: 22.3pt; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-style: italic;">Other Rights</font><font style="font-size: 10pt;">. Holders of our common stock have no preferences or
        conversion or exchange rights. Shares of our common stock will not be liable for further calls or assessments by us and are not subject to redemption.</font></div>
    <div style="text-align: justify; text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Certain Provisions Having Potential Anti-Takeover Effects</div>
    <div style="text-align: justify; text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif; font-style: italic;">&#160;</div>
    <div style="text-indent: 22.3pt; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-style: italic;">General. </font><font style="font-size: 10pt;">The following is a summary of the material provisions of
        the Nevada Revised Statues, which we refer to as the NRS, and our charter and bylaws that address matters of corporate governance and the rights of stockholders. Certain of these provisions may delay or prevent takeover attempts not first approved
        by our Board of Directors (including takeovers which certain stockholders may deem to be in their best interests). These provisions also could delay or frustrate the removal of incumbent directors or the assumption of control by stockholders. The
        primary purpose of these provisions is to encourage negotiations with our management by persons interested in acquiring control of our company. All references to the charter and bylaws are to our charter and bylaws in effect on the date of this
        prospectus.</font></div>
    <div><br>
    </div>
    <div>
      <div style="text-indent: 20pt; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-style: italic;">Combinations with Interested Stockholder.&#160;&#160;&#160;</font><font style="font-size: 10pt;">Sections&#160;78.411-78.444,
          inclusive, of the NRS contain provisions governing combinations with an interested stockholder. For purposes of the NRS, &#8220;combinations&#8221; include: (i)&#160;any merger or consolidation with any interested stockholder, (ii)&#160;any sale, lease, exchange,
          mortgage, pledge, transfer or other disposition to any interested stockholder of corporate assets with an aggregate market value equal to more than 5% of the aggregate market value of the corporation&#8217;s consolidated assets, more than 5% of the
          aggregate market value of outstanding shares of the corporation or more than 10% of the earning power or net income of the corporation, (iii)&#160;the issuance to any interested stockholder of voting shares (except pursuant to a share dividend or
          similar proportionate distribution) with an aggregate market value equal to 5% or more of the aggregate market value of all the outstanding shares of the corporation, (iv)&#160;the adoption of the dissolution of the corporation if proposed by or on
          behalf of any interested stockholder, (v)&#160;any reclassification of securities, recapitalization or corporate reorganization that will have the effect of increasing the proportionate share of the corporation&#8217;s outstanding voting shares held by any
          interested stockholder and (vi)&#160;any receipt by the interested stockholder of the benefit (except proportionately as a stockholder) of any loan, advance, guarantee, pledge or other financial assistance. For purposes of the NRS, an &#8220;interested
          stockholder&#8221; is defined to include any beneficial owner of more than 10% of any class of the voting securities of a Nevada corporation and any person who is an affiliate or associate of the corporation and was at any time during the preceding
          two&#160;years the beneficial owner of more than 10% of any class of the voting securities of the Nevada corporation.</font></div>
    </div>
    <div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">10</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-indent: 20pt; font-family: 'Times New Roman',Times,serif;">Subject to certain exceptions, the provisions of the NRS statute governing combinations with interested stockholders provide that a Nevada corporation may not engage in a
        combination with an interested stockholder for two&#160;years after the date that the person first became an interested stockholder unless the combination or the transaction by which the person first became an interested stockholder is approved by the
        Board of Directors before the person first became an interested stockholder, or unless the combination is approved by the Board of Directors and sixty&#160;percent of the corporation&#8217;s voting power not beneficially owned by the interested stockholder,
        its affiliates and associates.</div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 22.5pt; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-style: italic;">&#160;Control Share Acquisitions.</font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;The NRS also contains a &#8220;control share acquisitions statute.&#8221; If applicable to a Nevada corporation this statute restricts the voting rights of certain stockholders referred to as &#8220;acquiring persons,&#8221; that acquire or offer
        to acquire ownership of a &#8220;controlling interest&#8221; in the outstanding voting stock of an &#8220;issuing corporation.&#8221; For purposes of these provisions, a &#8220;controlling interest&#8221; means with certain exceptions the ownership of outstanding voting stock
        sufficient to enable the acquiring person to exercise one-fifth or more but less than&#160;one-third,&#160;one-third&#160;or more but less than a majority, or a majority or more of all voting power in the election of directors; &#8220;issuing corporation&#8221; means a
        Nevada corporation that has 200 or more stockholders of record, at least 100 of whom have addresses in Nevada appearing on the stock ledger of the corporation at all times during the 90&#160;days immediately preceding such date, and which does business
        in Nevada directly or through an affiliated corporation. The voting rights of an acquiring person in the affected shares will be restored only if such restoration is approved by the holders of a majority of the voting power of the corporation. The
        NRS allows a corporation to &#8220;opt-out&#8221; of the control share acquisitions statute by providing in such corporation&#8217;s articles of incorporation or bylaws that the control share acquisitions statute does not apply to the corporation or to an
        acquisition of a controlling interest specifically by types of existing or future stockholders, whether or not identified. The Company has not opted out of this statute.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 22.5pt; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-style: italic;">Authorized But Unissued Shares. </font><font style="font-size: 10pt;">Nevada law does not require
        stockholder approval for any issuance of authorized shares. Authorized but unissued shares may be used for a variety of corporate purposes, including future public or private offerings to raise additional capital or to facilitate corporate
        acquisitions. One of the effects of the existence of authorized but unissued shares may be to enable our Board of Directors to issue shares to persons friendly to current management, which issuance could render more difficult or discourage an
        attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise, and thereby protect the continuity of our management and possibly deprive the stockholders of opportunities to sell their shares of common stock at
        prices higher than prevailing market prices.</font></div>
    <div style="text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif; font-style: italic;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">11</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-indent: 22.5pt; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-style: italic;">Preferred Stock</font><font style="font-size: 10pt;">. Under the terms of our charter, our Board of
        Directors is authorized to issue shares of preferred stock in one or more series without stockholder approval. Our Board of Directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights,
        dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. The purpose of authorizing our Board of Directors to issue preferred stock and determine its rights and preferences is to
        provide flexibility and eliminate delays associated with a stockholder vote on specific issues. However, the ability of our Board of Directors to issue preferred stock and determine its rights and preferences may have the effect of delaying or
        preventing a change in control.</font></div>
    <div style="text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-indent: 22.5pt; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-style: italic;">Classified Board. </font><font style="font-size: 10pt;">We have a classified Board of Directors
        consisting of three classes of directors. A classified board is one in which a certain number, but not all, of the directors are elected on a rotating basis each year. This method of electing directors makes changes in the composition of our Board
        more difficult, and thus a potential change in control may be a lengthier process. The existence of our classified Board reduces the possibility that a third party could effect an unsolicited change in control of our Board. Since our classified
        Board will increase the amount of time required for a takeover bidder to obtain control of us without the cooperation of the Board, even if the takeover bidder were to acquire a majority of our outstanding common stock, the existence of our
        classified Board could tend to discourage certain tender offers which stockholders might feel would be in their best interests. Our classified Board will likely allow management, if confronted by a proposal from a third party who has acquired a
        block of our common stock, sufficient time to review the proposal and appropriate alternatives to the proposal and to attempt to negotiate a better transaction, if possible, for our stockholders.</font></div>
    <div><br>
    </div>
    <div style="text-indent: 22.5pt; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-style: italic;">Special Meetings of Stockholders.</font><font style="font-size: 10pt;"> Our bylaws provide that special
        meetings of stockholders may be called only by our Board of Directors or the Chairman of the Board.</font></div>
    <div style="text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif;">&#160;<font style="font-style: italic;">&#160;</font></div>
    <div style="text-indent: 22.5pt; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-style: italic;">Filling Vacancies.</font><font style="font-size: 10pt;"> Vacancies occurring in our Board of Directors and
        newly created directorships resulting from an increase in the authorized number of directors may be filled by a majority of the remaining directors, even if less than a quorum.</font></div>
    <div style="text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-indent: 22.5pt; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-style: italic;">Removal of Directors by Stockholders. </font><font style="font-size: 10pt;">Under the terms of our
        charter, stockholders may remove directors with or without cause with the affirmative vote of holders of 75% of the voting power of all of the then-outstanding shares of our capital stock then entitled to vote at an election of directors, voting
        together as a single class.</font></div>
    <div style="font-family: 'Times New Roman',Times,serif; font-style: italic;">&#160;</div>
    <div style="text-indent: 22.5pt; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-style: italic;">Amendment of Bylaws.</font><font style="font-size: 10pt;"> Our bylaws may be amended by our Board of
        Directors or by the holders of at least 75% of the voting power of our company.</font></div>
    <div style="text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-indent: 22.5pt; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-style: italic;">Amendment of Certain Charter Provisions. </font><font style="font-size: 10pt;">Under the terms of our
        charter, amending certain charter provisions requires the affirmative vote of the holders of at least 75% of the voting power of all of the then-outstanding shares of our capital stock entitled to vote thereon, voting together as a single class.
        The provisions subject to such heightened requirement include those relating to stockholder action by written consent, the calling of special meetings, board classification, the filling of board vacancies, the removal of directors and the ability
        to amend our bylaws, among others.</font></div>
    <div style="text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif; font-style: italic;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">12</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-indent: 22.5pt; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-style: italic;">Advance Notification of Stockholder Nominations and Proposals</font><font style="font-size: 10pt;">. Our
        bylaws establish advance notice procedures with respect to the nomination of persons for election as directors, other than nominations made by or at the direction of our Board of Directors, and stockholder proposals for business.</font></div>
    <div style="text-align: justify; text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 22.3pt; font-family: 'Times New Roman',Times,serif; font-style: italic;">Stockholder Nominees; Stockholder Proposals.</div>
    <div style="text-align: justify; text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-indent: 22.3pt; font-family: 'Times New Roman',Times,serif;">In order for a stockholder to nominate a candidate for director at, or bring any business before, an annual meeting of stockholders, under our bylaws, timely notice of the
      nomination or business must be received by us in advance of the meeting. To be timely, a stockholder&#8217;s notice must be delivered to or mailed and received by our Secretary at our principal executive offices not less than 90 days nor more than 120 days
      prior to the one-year anniversary of the date on which we first mailed the proxy materials for the preceding year&#8217;s annual meeting of stockholders; provided, however, that if the meeting is convened more than 30 days prior to or delayed more than 60
      days after the anniversary of the preceding year&#8217;s annual meeting, to be timely a stockholder&#8217;s notice must be received not earlier than the close of business on the 120th day prior to the date of such annual meeting and not later than the close of
      business on the later of the 90th day prior to the date of such annual meeting or, if the first public announcement of the date of such annual meeting is less than 100 days prior to the date of such annual meeting, the 10th day following the day on
      which public announcement of the date of such meeting is first made by us.</div>
    <div><br>
    </div>
    <div style="text-indent: 22.3pt; font-family: 'Times New Roman',Times,serif;">The stockholder sending the notice of nomination or proposed business must describe various matters, including the following:</div>
    <div style="text-indent: -13.5pt; margin-left: 36pt; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z6d062e3b3ebe422dbed9059827b22d51">

        <tr>
          <td style="width: 4.35%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 3.62%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#9679;</div>
          </td>
          <td style="width: 92.03%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">as to each person whom the stockholder proposes to nominate for election as a director, all information relating to such person as would be required to be disclosed in solicitations of
              proxies for election of such nominee as a director pursuant to Regulation 14A under the Exchange Act;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4.35%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 3.62%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 92.03%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4.35%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 3.62%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#9679;</div>
          </td>
          <td style="width: 92.03%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;(i) the name and address of such stockholder, as they appear on our books and of such beneficial owner or Control Person (as defined in our bylaws), if any, (ii) the number of our shares
              which are, directly or indirectly, owned beneficially and of record by such stockholder and such beneficial owner or Control Person, if any (iii) a representation that the stockholder intends to appear at the meeting in person or by proxy to
              submit the business specified in such notice, (iv) if the notice relates to any business other than a nomination of director(s), a brief description of the business desired to be brought before the meeting, including the complete text of any
              resolutions proposed for consideration, and the reasons for conducting such business at the meeting, (v) any direct or indirect personal or other interest of the stockholder in the business to be submitted, (vi) a description of any
              agreement, arrangement or understanding (including any derivative or short positions, profit interests, options, hedging transactions, and borrowed or loaned shares) that has been entered into as of the date of the stockholder&#8217;s notice by, or
              on behalf of, such stockholder or beneficial owner and by any Control Person or any other person acting in concert with any of the foregoing, the effect or intent of which is to mitigate loss, manage risk or benefit from changes in the share
              price of any class of our stock, or maintain, increase or decrease the voting power of the stockholder or beneficial owner with respect to shares of our stock, and a representation that the stockholder will notify us in writing within five
              business days after the record date for such meeting of any such agreement, arrangement or understanding in effect as of the record date for the meeting, (vii) a representation whether the stockholder or the beneficial owner, if any, and any
              Control Person will engage in a solicitation with respect to the nomination or business and, if so, the name of each participant (as defined in Item 4 of Schedule 14A under the Securities Exchange Act of 1934) in such solicitation and whether
              such person intends or is part of a group which intends to deliver a proxy statement and/or form of proxy to holders of at least the percentage of our outstanding stock required to approve or adopt the business to be proposed (in person or by
              proxy) by the stockholder and (viii) any other information relating to such stockholder, beneficial owner or Control Person, if any, that would be required to be disclosed in a proxy statement and form of proxy or other filings required to be
              made in connection with solicitations of proxies for, as applicable, the proposal and/or for the election of directors in a contested election pursuant to Section 14 of the Securities Exchange Act of 1934 and the rules and regulations
              promulgated thereunder.</div>
          </td>
        </tr>

    </table>
    <div style="text-indent: 22.3pt; font-family: 'Times New Roman',Times,serif; font-style: italic;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">13</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif;">These provisions are intended to enhance the likelihood of continuity and stability in the composition of the Board and in policies formulated by the Board and to discourage
      certain types of transactions that may involve an actual or threatened change of control of our company. These provisions are designed to reduce our vulnerability to an unsolicited proposal for a takeover that does not contemplate the acquisition of
      all of our outstanding shares or an unsolicited proposal for the restructuring or sale of all or part of our company.</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Limitations on Director Liability</div>
    <div style="text-align: justify; text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif;">Our charter provides that our directors shall generally not be liable to us or any of our stockholders for damages for breach of duty as a director. This provision will
      eliminate such liability except for (i) any breach of the director&#8217;s duty of loyalty to us or to our stockholders, (ii) acts and omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) liability for
      unlawful payment of dividends or unlawful stock purchases or redemptions in violation of the NRS, and (iv) any transaction from which the director derived an improper personal benefit.</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Indemnification of Directors and Officers</div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif;">Section 78.7502(1) of the NRS provides that a corporation may, and our charter and bylaws provide that we shall, indemnify any person who was or is a party or is threatened
      to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, or an Action, by reason of the fact that he is or was our director, officer, employee or agent or is or
      was serving at our request in such capacity in another corporation, partnership, joint venture, trust or other enterprise, or the Indemnified Party, against expenses (including attorney&#8217;s fees), judgments, fines and amounts paid in settlement
      actually and reasonably incurred by him in connection with such Action, suit or proceeding if he acted in good faith and in a manner he reasonably believed to be in or not opposed to our best interests, and, with respect to any criminal action or
      proceeding, had no reasonable cause to believe his conduct was unlawful; provided, however, no indemnification shall be made in respect of any Action by or in our right if the Indemnified Party shall have been adjudged by a court of competent
      jurisdiction, after exhaustion of any appeals, to be liable to us, unless and only to the extent that the court shall determine that, despite the adjudication of liability but in view of all circumstances, such person is fairly and reasonably
      entitled to indemnity.&#160;&#160;</div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">14</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif;">Under the NRS, the directors have a fiduciary duty to us that is not eliminated by this provision of our charter and, in appropriate circumstances, equitable remedies such as
      injunctive or other forms of non-monetary relief will remain available.&#160;&#160;In addition, each director will continue to be subject to liability under the NRS for breach of the director&#8217;s duty of loyalty to us for acts or omissions which are found by a
      court of competent jurisdiction to not be in good faith or involve intentional misconduct, for knowing violations of law, for actions leading to improper personal benefit to the director, and for payment of dividends or approval of stock repurchases
      or redemptions that are prohibited by the NRS. This provision also does not affect the directors&#8217; responsibilities under any other laws, such as the federal securities laws or state or federal environmental laws.</div>
    <div><br>
    </div>
    <div style="text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif;">Furthermore, Section 78.7502(3) of the NRS provides that determination of an Indemnified Party&#8217;s eligibility for indemnification by us shall be made on a case-by-case basis
      by: (i) the stockholders; (ii) the board of directors by a majority vote of a quorum consisting of directors who were not parties to the action, suit or proceeding; (iii) independent legal counsel&#8217;s written opinion if: (1) a majority vote of a quorum
      consisting of directors who were not parties to the action, suit or proceeding so orders; or (2) a quorum consisting of directors who were not parties to the action, suit or proceeding cannot be obtained.</div>
    <div><br>
    </div>
    <div style="text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif;">Lastly, Section 78.752(1) of the NRS empowers a corporation to purchase and maintain insurance or make other financial arrangements with respect to liability arising out of
      the actions or omissions of directors, officers, employees or agents in their capacity or status as such, whether or not the corporation has the authority to indemnify him against such liability.&#160;&#160;</div>
    <div><br>
    </div>
    <div style="text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif;">Our charter provides that, to the fullest extent permitted by the NRS, no director or officer shall be personally liable to us or to our stockholders for monetary damages for
      breach of fiduciary duty as a director or an officer, except to the extent that such exemption from liability or limitation thereof is not permitted under the NRS currently in effect or as the same may be amended.&#160; If the NRS is amended to further
      eliminate or limit or authorize corporate action to further eliminate or limit the liability of directors or officers, the liability of our directors and officers shall be eliminated or limited to the fullest extent permitted by the NRS, as so
      amended from time to time.&#160; No repeal or modification of this provision of our charter will apply to or have any effect on the liability or alleged liability of any of our directors or officers for or with respect to any acts or omissions of such
      directors or officers occurring prior to such repeal or modification.</div>
    <div><br>
    </div>
    <div style="text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif;">Our bylaws provide that we will indemnify and hold harmless any person who was or is a party or is threatened to be made a party to any threatened, pending or completed
      action, suit or proceeding, whether civil, criminal, administrative or investigative, in such manner, under such circumstances and to the fullest extent permitted by our charter and the NRS.</div>
    <div><br>
    </div>
    <div style="text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons under the provisions discussed
      above or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#160;</font>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">15</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Transfer Agent</div>
    <div style="text-align: justify; text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 22.5pt; font-family: 'Times New Roman',Times,serif;">The transfer agent for our common stock is Transhare Corporation.</div>
    <div><br>
    </div>
    <div style="text-align: center; margin-top: 6pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><a name="PLANOFDISTRIBUTION"><!--Anchor--></a>PLAN OF DISTRIBUTION</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; margin-bottom: 8pt; font-family: 'Times New Roman',Times,serif;">The common stock may be sold or distributed from time to time by the selling securityholders. The shares may be sold or distributed directly to one or more
      purchasers, including pledgees, or through brokers or dealers who may act solely as agents or may acquire the shares as principals. The shares may be sold at market prices prevailing at the time of sale, at prices related to such prevailing market
      prices, at negotiated prices or at fixed prices, which may be changed. When we refer to the &#8220;selling securityholders&#8221; in this section, we mean the selling securityholders listed in the section entitled &#8220;<a href="#SELLINGSECURITYHOLDERS">Selling
        Securityholders</a>&#8221;, as well as their respective pledgees, donees, assignees, transferees and other successors-in-interest.</div>
    <div style="margin-bottom: 8pt;"><font style="font-family: 'Times New Roman',Times,serif;">&#160;</font><font style="display: inline-block; text-indent: 0px; width: 36pt;" class="TRGRRTFtoHTMLTab">&#160;</font><font style="font-family: 'Times New Roman',Times,serif;">The distribution of the shares of common stock may be effected in one or more of the following methods:&#160;</font></div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z06f76a99ef4840718db66c20ddffe4c6">

          <tr>
            <td style="width: 76.5pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 58.5pt; font-family: 'Times New Roman',Times,serif;">&#8226;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="font-family: 'Times New Roman',Times,serif;">underwritten offerings;</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8b25fa72381a464eb937767a91bec5dd">

          <tr>
            <td style="width: 76.5pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 58.5pt; font-family: 'Times New Roman',Times,serif;">&#8226;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">ordinary brokers transactions and transactions in which the broker solicits purchasers;</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1282bbc6914c4a559645296360e1ec37">

          <tr>
            <td style="width: 76.5pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 58.5pt; font-family: 'Times New Roman',Times,serif;">&#8226;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="font-family: 'Times New Roman',Times,serif;">purchases by brokers or dealers as principal and resale by such purchasers for their own accounts pursuant to this prospectus;</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za532d201341240a0aea3d02711527c46">

          <tr>
            <td style="width: 76.5pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 58.5pt; font-family: 'Times New Roman',Times,serif;">&#8226;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="font-family: 'Times New Roman',Times,serif;">block trades in which the broker-dealer so engaged will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the
                transaction;</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7fa0234446a94926a4e7a8abc003f0f9">

          <tr>
            <td style="width: 76.5pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 58.5pt; font-family: 'Times New Roman',Times,serif;">&#8226;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="font-family: 'Times New Roman',Times,serif;">to or through market makers or into an existing market for the common stock;</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd0331eb35c6542db8d0b814a712908a8">

          <tr>
            <td style="width: 76.5pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 58.5pt; font-family: 'Times New Roman',Times,serif;">&#8226;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="font-family: 'Times New Roman',Times,serif;">in other ways not involving market makers or established trading markets, including direct sales to purchasers or sales effected through agents;</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4c425046a331411885e88ae3788fd5de">

          <tr>
            <td style="width: 76.5pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 58.5pt; font-family: 'Times New Roman',Times,serif;">&#8226;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="font-family: 'Times New Roman',Times,serif;">through transactions in options, swaps or other derivatives, whether exchange listed or otherwise;</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3dbdd8650fff46bc8f895145891730c2">

          <tr>
            <td style="width: 76.5pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 58.5pt; font-family: 'Times New Roman',Times,serif;">&#8226;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="font-family: 'Times New Roman',Times,serif;">through the settlement of short sales;</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z883f63411ce34a3ca3d9ab8bba4f872d">

          <tr>
            <td style="width: 76.5pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 58.5pt; font-family: 'Times New Roman',Times,serif;">&#8226;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="font-family: 'Times New Roman',Times,serif;">in privately negotiated transactions; or</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z32511cfca9734252a594b220424f18a6">

          <tr>
            <td style="width: 76.5pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; margin-left: 58.5pt; font-family: 'Times New Roman',Times,serif;">&#8226;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="font-family: 'Times New Roman',Times,serif;">any combination of the foregoing, or by any other legally available means.</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div style="margin-bottom: 12pt;"><font style="font-family: 'Times New Roman',Times,serif;">&#160;&#160;</font><font style="display: inline-block; text-indent: 0px; width: 36pt;" class="TRGRRTFtoHTMLTab">&#160;</font><font style="font-family: 'Times New Roman',Times,serif;">In addition, any shares that qualify for sale pursuant to Rule&#160;144 under the Securities Act may be sold under Rule&#160;144 rather than pursuant to this prospectus.&#160; If a selling securityholder uses one or more underwriters in the
        sale, such underwriter(s) will acquire the shares of our common stock covered by this prospectus for their own account. The underwriter(s) may resell the shares of our common stock in one or more transactions, including negotiated transactions, at
        a fixed public offering price or at varying prices determined at the time of sale.</font></div>
    <div style="text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">To the extent required, this prospectus may be amended or supplemented from time to time to describe a specific plan of distribution, including the names
      of any underwriters, the purchase price and the proceeds the selling securityholders will receive from the sale, any underwriting discounts and other items constituting underwriters' compensation, any initial public offering price and any discounts
      or concessions allowed or reallowed or paid to dealers, and any other information we believe to be material.</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">16</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">In connection with distributions of the shares or otherwise, the selling securityholders may enter into hedging transactions with broker-dealers or other
      financial institutions. In connection with such transactions, broker-dealers or other financial institutions may engage in short sales of the common stock in the course of hedging the positions they assume with the selling securityholders. The
      selling securityholders may also sell the common stock short and redeliver the shares to close out such short positions. The selling securityholders may also enter into option or other transactions with broker-dealers or other financial institutions
      which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to
      reflect such transaction). The selling securityholders may also pledge shares to a broker-dealer or other financial institution, and, upon a default, such broker-dealer or other financial institution may effect sales of the pledged shares pursuant to
      this prospectus (as supplemented or amended to reflect such transaction).</div>
    <div style="text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">Brokers, dealers or agents participating in the distribution of the shares of common stock may receive compensation in the form of discounts, concessions
      or commissions from the selling securityholders and/or the purchasers of shares of common stock for whom such broker-dealers may act as agent or to whom they may sell as principal, or both.&#160; Such compensation as to a particular broker-dealer may be
      in excess of customary commissions.&#160; The selling securityholders and any broker-dealers acting in connection with the sale of the shares of common stock hereunder may be deemed to be underwriters within the meaning of Section 2(11) of the Securities
      Act, and any commission received by them and any profit realized by them on the resale of shares of common stock as principals may be deemed underwriting compensation under the Securities Act.&#160; Neither we nor the selling securityholders can presently
      estimate the amount of that compensation.&#160; We know of no existing arrangements between the selling securityholders and any such broker, dealer or agent relating to the sale or distribution of the shares of common stock.</div>
    <div style="text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">&#160;The anti-manipulation rules of Regulation&#160;M under the Exchange Act may apply to sales of shares in the market and to the activities of the selling
      securityholders and their affiliates, which may restrict certain activities of, and limit the timing of purchases and sales of securities by, the selling securityholders and other persons participating in a distribution of securities.&#160; In addition,
      we will make copies of this prospectus available to the selling securityholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act.&#160; The selling securityholders may indemnify any broker-dealer that participates
      in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act.</div>
    <div style="text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">At the time a particular offer of shares is made, if required, a prospectus supplement will be distributed that will set forth the number of shares of our
      common stock being offered, the method of distribution and the terms of the offering, including the name or names of any underwriters, dealers or agents, the purchase price paid by any underwriter, any discount, commission and other item constituting
      compensation, any discount, commission or concession allowed or reallowed or paid to any dealer, and the proposed selling price to the public</div>
    <div style="text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">In order to comply with the securities laws of some states, if applicable, the common stock may be sold in these jurisdictions only through registered or
      licensed brokers or dealers. In addition, in some states, the common stock may not be sold unless it has been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied with.</div>
    <div style="text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">The specific terms of the lock-up provisions, if any, in respect of any given offering will be described in the applicable prospectus supplement.</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">17</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">We have agreed with the selling securityholders to keep the registration statement, of which this prospectus constitutes a part, effective until none of
      the selling securityholders owns any Warrants or shares of common stock issuable upon the exercise thereof.</div>
    <div style="text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">There can be no assurance that the selling securityholders will sell any or all of the shares of common stock covered by this prospectus.</div>
    <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><a name="LEGALMATTERS"><!--Anchor--></a>LEGAL MATTERS</div>
    <div style="text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">The validity of the common stock offered by this prospectus is being passed upon by Certilman Balin Adler &amp; Hyman, LLP, 90 Merrick Avenue, East Meadow,
      New York. As of April 18, 2024, Certilman Balin Adler &amp; Hyman, LLP owned 41 shares of our common stock.</div>
    <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><a name="EXPERTS"><!--Anchor--></a>EXPERTS</div>
    <div style="text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman',Times,serif;">Our consolidated financial statements as of December&#160;31, 2022 and 2023 and for the years then ended appearing in our <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1505497/000149315224012056/form10-k.htm">Annual Report on Form 10-K for the year ended December 31, 2023</a> have been incorporated by reference into this prospectus in reliance upon the report
      of Marcum LLP, an independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing.</div>
    <div><br>
    </div>
    <div style="margin-top: 4.25pt;"><br>
    </div>
  </div>
  <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">18</font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !] 44# 2(  A$! Q$!_\0
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MK2BH<FU8I)(6BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "DI:2@ Q5+4--M]1@\N9!D'*MCD&KU(<T
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MH!%*.E3*I*4.0:BD[G)^/?!\/B_0VMV&)TYC/O7B^BWGB[X=W,EM]DEEM\X
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' "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
